Company profile: KalVista Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of oral plasma kallikrein inhibitors for on-demand treatment of hereditary angioedema (HAE), including Sebetralstat being evaluated in the KONFIDENT Phase 3 Trial; developer of oral Factor XIIa inhibitors to prevent thrombosis with reduced bleeding risk; and other oral therapies targeting the kallikrein-kinin system, including HAE. An ophthalmology company with a focus on diabetic macular edema (DME).
Products and services
- Sebetralstat: An oral, on-demand plasma kallikrein inhibitor engineered to treat hereditary angioedema attacks, designed to be taken orally as needed during attacks
- KONFIDENT Phase 3 Trial: A Phase 3 clinical study evaluating the safety and efficacy of Sebetralstat administered on-demand for hereditary angioedema attacks
- Oral Plasma Kallikrein Inhibitors: Oral drugs in development targeting the kallikrein-kinin system to treat diseases mediated by that pathway, including hereditary angioedema.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to KalVista Pharmaceuticals
Manhattan Pharma
HQ: United States
Website
- Description: Provider of specialty healthcare product development and commercialization focused on innovative treatments for underserved patient populations, advancing a portfolio of product candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Manhattan Pharma company profile →
Cullgen
HQ: United States
Website
- Description: Provider of drug discovery services leveraging its uSMITE platform to develop targeted protein degraders using novel E3 ligands for diseases lacking effective therapies, including cancer, inflammation, autoimmune, and neurodegenerative disorders; pipeline includes CG001419, an orally bioavailable pan-TRK degrader in phase I/II clinical trial for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cullgen company profile →
Orbis Biosciences
HQ: United States
Website
- Description: Provider of scalable materials encapsulation solutions, enabling precise control of particle size, encapsulation material, shell thickness, and porosity for applications in drug formulations, agricultural compounds, and novel food processing techniques.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orbis Biosciences company profile →
Woolsey Pharmaceuticals
HQ: United States
Website
- Description: Provider of investigational oral fasudil (BRAVYL) for indications including dementia-related wandering, Progressive Supranuclear Palsy, Corticobasal Syndrome, and Amyotrophic Lateral Sclerosis; conducts phase 2a studies (FOUND, REAL, ROCKIT-1) to evaluate efficacy, safety, and biomarkers; and maintains an expanded access policy for serious or life-threatening conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Woolsey Pharmaceuticals company profile →
Redwood Bioscience
HQ: United States
Website
- Description: Provider of precision protein-chemical engineering to develop optimized, novel biotherapeutics using site-specific modification technology to create homogenous biologic-synthetic conjugates; offering microscale perfusion-based cultivation for Pichia pastoris, E. coli recombinant proteins, CagA diagnostic proteins, and KRAS G12D recombinant protein vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Redwood Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for KalVista Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to KalVista Pharmaceuticals
2.2 - Growth funds investing in similar companies to KalVista Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for KalVista Pharmaceuticals
4.2 - Public trading comparable groups for KalVista Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →